Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Similar documents
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

Personalized. Health in Canada

MARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM

-YOUR PARTNER IN RESEARCH AND DEVELOPMENT

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

Healthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016

Research and development case study. Human health research

Report on the implementation of the 5 steps. Natacha Beicht-Claude, Human Resources Manager, LIH

Translational Medicine From Discovery to Health

Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society

Biobanks in Spain. An overview.

Joint Technology Initiative: Innovative Medicine Initiative

EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008

NHS ENGLAND BOARD PAPER

Using local RWD to drive global therapeutic advancements.

Nordic Register and Biobank Data

Konica Minolta to Acquire Invicro (US)

Genomic Medicine in France

IRDiRC: International Rare Diseases Research Consortium

Nanotechnology and Advanced Materials for more effective Healthcare

ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure

SSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview

An Taoiseach Opens New Research Centres to Benefit Frontline Patient Care

The Hellenic Network of Biobanks-BBMRI-GR Dr. S.Kolyva Representative of Greece in the General Assembly of BBMRI-ERIC

Personalized Medicine

LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

Novel tool to monitor therapeutic response. patients with viral leukemia

Research Strategy

Alps Bio Cluster Biotech and medtech in Alpine Space

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017

Future of the Project. BioMedBridges 3rd Annual General Meeting 18 February 2015, Munich Janet Thornton

BIOMEDICAL RESEARCH CENTRES

"EU-funding of Microbiome research under FP7 and H2020"

Opportunities for industry/smes in EU-funded health research

PERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients

REIMAGINING DRUG DEVELOPMENT:

UCL courses that require ATAS

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

IDC Market Glance: Value-Based Health

Proposal of Recommendations for a Personalised Precision Medicine National Strategy. Anticipating the future. Accelerating changes.

Where are your medical records?

INFECTIOUS DISEASES WE ARE LEADING THE WAY.

Rare Diseases: Challenges and Opportunities NIH Perspective

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org

MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE

2017 Precision Medicine Study

New Frontiers in Personalized Medicine

The Integrated Biomedical Sciences Graduate Program

Real World Data Pilotprosjekt mellom LMI og Kreftregisteret; hvilken nytte kan industri og myndigheter ha av dette?

Cancer ImmunoTherapy Accelerator (CITA) Dr Shalini Jadeja

BC Platforms Clinical and Genomic Data Integration Platform. Päivi Tikka-Kleemola, PhD Service Manager

GMO Technology Conference

Greenwood Genetic Center

Horizon H2020 Training for TECPAR Opportunities to participate in European Research Projects

SINGAPORE SCIENTISTS DEVELOP DNA-ALTERING TECHNOLOGY TO TACKLE DISEASES Finding could lead to new therapeutics for diseases

Can/How do we put data intensive biology in the picture?

Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare

EUCLID EUropean CLInical Trials Services Platform & Development

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA

Use of Big Data to Support Regulatory Decision Making

Real World Evidence Transforming patient care

BUILDING REVENUE AND LOYALTY WITH DIGITAL HEALTH. London, April 4-5.4, 2017 Janne-Olli Järvenpää, CEO Mehiläinen Oy

Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

CDA vs Archetypes: Use Cases March Tomaž Gornik, Co-founder and CEO

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

State of the Art in Data Management for Precision Medicine & Genomics. March 8, pm 3 pm ET

European Induced Pluripotent Stem Cell Bank

The importance of international collaboration for rare diseases research: a European perspective

Malaria Research Capability Strengthening in Africa

compact Mental Health

Leveraging an Academic-Industry Partnership for Commercial Success

Telemedicine, data management, patient benefit - ehealth architectures controlled by patients for treatment and biomedical research

Goals of pharmacogenomics

A gateway to academic excellence for Biotech and Pharma

Overview of Health Informatics. ITI BMI-Dept

SMEs in IMI2 Calls for Proposals

Ethical Governance Framework

Funding AMR research: the UK Research Councils John Savill

European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013

17/06/2014. GTA West DI r Project. Bringing Standardization into a non Standard World. Why is GTA West DI-r Necessary? What is the GTA West DI-r?

leading the way in research & development

This Webcast Will Begin Shortly

Operations Department, Research Support Division

Applications of Big Data in Evidence-Based Medicine

Horizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.

HL7 Plenary EHR In Canada

ORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet

Strategies to increase profitability in Hospitals

Transcription:

FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Research in Luxembourg Luxembourg : a young research location Creating structures 1987 : First law on the public-sector research 1987 : First public Research Centres (LIH and LISER) 1999 : National Research Fund (FNR) 2003 : University of Luxembourg 2009 : Luxembourg Centre for Systems Biomedecine (LCSB) 2009 : Interdisciplinary Centre for Security Reliability and Trust (SnT) 2012 : Max-Planck Institute Luxembourg, dedicated to International and European Procedural Law 2015 : Creation of LIST (Luxembourg Institute of Science and Technology) 2015 : BELVAL Luxembourg Research and Innovation Campus 1

Research in Luxembourg Luxembourg : a young research location Sustained efforts 2

Research in Luxembourg Belval Luxembourg s Research and Innovation Campus 120 hectares site of Luxembourg's largest steel foundry 750 MEUR urban renewal project 20 new buildings All major research and innovation actors Around 7,000 students and 3,000 teaching staff and researchers 3

Development of the Luxembourgish Economy BioHealth Ecoinnovation ICT Materials Space 4 4

Scientific output (SCImago data for Field of Medicine) 5

Biomedical research from a Luxembourgish perspective 6

Research Actors Biomedical and Health research Systems Biomedicine Parkinson s Infection & Immunity Oncology Population Health Proteomics Social Influences Tumor Biology Psychophysiology Health research Environment Materials Health IT Neuropathology Genetics 7

Research Actors Biomedical and Health research Systems Biomedicine Parkinson s CANCER Infection & Immunity Oncology Population Health Immunology and Inflammation Neurodegeneration Parkinson s Social Influences Proteomics Tumor Biology Population Health and Socio-environmental factors Psychophysiology Health research Environment Materials Health IT Neuropathology Genetics 8

Biomedicine Quo vadis? From Data to Knowledge Psycho-social Food Toxins Genes Stress Individual level Population level Mechanistic models, Prediction State of health and disease Prevention Diagnosis Therapy Education Policy Development 9

Personalized Medicine Consortium (PMC) ~ 150M investment by Lux Gouvernment IBBL LCSB Lung Cancer Project (PPM) Institute for Systems Biology (Seattle) Translational Genomics Research Institute (Arizona) Partnership in Personalised Medicine Consortium of several U.S. centres 10

LCSB From systems biology to systems medicine Family Studies Patients Longitudinal Cohorts Pathway and Network Analysis Computational Models Machine Learning Yeast Zebrafish Mouse Organ on a chip Microbiome Human 11

LCSB: At the interface of IT and medicine Bio- and Medical Informatics Integration of Clinical and Non-Clinical Data Computational Disease Modelling International Data Hub 12

New ELIXIR node in Luxembourg LCSB Repository of biological data Decentralised Hub & Nodes structure for hosting data Assessed among the 3 strategically most important European infrastructures Luxembourg became node for translational medicine data 13

DEPARTEMENT OF INFECTION AND IMMUNITY DEPARTEMENT OF ONCOLOGY DEPARTEMENT OF POPULATION HEALTH 14

LIH current strategy Translational and personalized medicine in Luxembourg, Clinical research in close collaboration with other national partners (hospitals, university, IBBL ) and become recognized in this domain at an EU level, To implement a state-of-the-art public health research firmly implemented in the EU context and serving the needs of the country, To develop research-oriented training & higher education activities in close collaboration with the University of Luxembourg

Clinical and Epidemiological Investigation Center CIEC Observational Healthy volunteers Exploratory Trials with IMP Phase II & III Registries CTU for Belgium & Luxembourg Coordination of EU trials STRASSEN r. Thomas Edison LUXEMBOURG CHL VISION-DMD 16

Integrated BioBank of Luxembourg An accredited & certified biobanking infrastructure Offering a full range of bioservices to academia, industry and EU consortia IBBL is an autonomous Institute organised within the Luxembourg Institute of Health (LIH) 17

Integrated BioBank of Luxembourg Preferred partner in EU projects: MINDACT study (Microarray In Node negative Disease may Avoid ChemoTherapy) BIOMARKAPD project of the EU Joint Programme for Neurodegenerative Disease (JPND) Research STORE (for Sustaining access to Tissue and data from Radiobiological Experiments), FP7 Programme IMI Cancer ID and IMI Litmus H2020 SPIDIA4P EATRIS host institution for Luxembourg 70+ active projects (40+ fee for service contracts) Key projects in LU: National centre for Excellence in Research on Parkinson's Disease (NCER-PD) (with LCSB, LIH, CHL) Plan National Cancer (with LNS, LU Hospitals) Key projects outside of LU: EORTC (European Organisation for Research and Treatment of Cancer): Scientific partner and biobank infrastructure BIG (Breast International Group, BIG) Aurora study 18

FNR s National Centre of Excellence in Research (NCER) Joint Research Program on Earlier Diagnosis of Parkinson s Disease 20M invest over 8 years 19

From banking and media to digital health Making use of current infrastructures and competences Finance ICT, Media, gaming Digital health 20 20

The Luxembourg Life Sciences ecosystem The Luxembourg Life Sciences environment 70 Cluster members o 46 companies o 14 service providers o 6 public research organisations o 4 strategic partners 21

Medicine of tomorrow Data-driven Personalised Patient-centered Preventive Need for systemic change in the healthcare system 22

Luxembourg Healthcare System 1 Payor 4 major hospitals for acute care and 5 smaller hospitals for specialized care ~ 98 public Pharmacies ~ 2200 Practitioners (incl. Dentists) Laboratories: 3 private Laboratory groups 1 national Laboratory (LNS) Each hospital has a laboratory 2 major providers for the home care domain (cover 97%) Up to 60 institutions for long term care 23

ehealth Agency in Luxembourg Exchange and sharing of medical data Define a national strategy (SDSI) promoting interoperability between healthcare information management systems. Develop and implement a common interoperability platform to support such data sharing and exchange 24

Agence esanté Platform and DSP goal Support for enhanced diagnostic and patient treatment High level of quality and security Usage of more structured data Reduction of costs 25

CLINNOVA Teaming proposal within H2020 widening The Gap: Clinical research in Luxembourg The Aim: Bridging between research and healthcare Saving Time: Through teaming up with strong partners Strong IT component: digital medicine, ehealth records, big data analytics Infrastructure for clinical research: research ward, clinical imaging, phase 1 CTC, etc. Firmly establish clincian-researchers in Luxembourg Complete the value-added chain for biomedicine in Luxembourg the continuum from basic research to patient application 26

FNR s international cooperation http://fnr.lu/fnr-international-cooperation/ 27

INTER: Multi-lateral international Collaborations 28

Thank you for your attention 29 29 /X X